<DOC>
	<DOCNO>NCT00550784</DOCNO>
	<brief_summary>RATIONALE : Giving chemotherapy peripheral stem cell transplant stop growth tumor cell stop divide kill . Giving colony-stimulating factor , G-CSF , certain chemotherapy drug , help stem cell move bone marrow blood collect store . More chemotherapy give prepare bone marrow stem cell transplant . The stem cell return patient replace blood-forming cell destroy chemotherapy . PURPOSE : This phase I trial study side effect best dose topotecan give together cyclophosphamide , paclitaxel , melphalan , cisplatin , follow autologous peripheral stem cell transplant treat patient stage III , stage IV , recurrent ovarian epithelial cancer , primary peritoneal cancer , fallopian tube cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Autologous Peripheral Stem Cell Transplant Treating Patients With Stage III , Stage IV , Recurrent Ovarian Epithelial Cancer , Primary Peritoneal Cancer , Fallopian Tube Cancer</brief_title>
	<detailed_description>OBJECTIVES : - To establish maximum tolerate dose ( MTD ) continuous infusion intravenous topotecan hydrochloride administer intraperitoneal ( IP ) cisplatin intravenous melphalan patient stage III , stage IV , recurrent ovarian epithelial cancer , primary peritoneal cancer , fallopian tube cancer . - To describe toxicity dose study . - To evaluate pharmacokinetics topotecan hydrochloride administer maximum tolerate dose cisplatin . - To confirm pharmacokinetic advantage high-dose IP cisplatin IP paclitaxel . - To obtain tissue time peritoneal catheter placement order evaluate molecular determinant apoptosis ( include p53 status , p21 gene expression , bcl-2 gene expression , bcl-2/bax ratio ) extent apoptosis TdT assay . - To evaluate molecular determinant DNA damage repair , include expression level ERCC1 MDR1 , HER2/neu expression immunohistochemistry . OUTLINE : This dose-escalation study topotecan hydrochloride . Patients undergo surgical placement intraperitoneal ( IP ) catheter . Tumor biopsy obtain surgery laboratory analysis molecular determinant apoptosis ( include p53 status , p21 gene expression , bcl-2 gene expression , bcl-2/bax ratio ) molecular determinant DNA damage repair ( include expression level ERCC1 MDR1 , HER2/neu expression immunohistochemistry ) . The extent apoptosis also assess use TdT assay . - Course 1 : Patients receive paclitaxel IP day 1 , cyclophosphamide IV day 2 , filgrastim ( G-CSF ) subcutaneously ( SC ) begin day 3 continue apheresis complete . Patients undergo apheresis ≥ 2.5 X 10^6 CD34-positive cells/kg collect . Two week later , patient proceed course 2 . - Course 2 : Patients receive cisplatin IP melphalan IV day -11 -4 topotecan hydrochloride continuous infusion 120 hour day -10 -6 . Patients receive 25 % peripheral blood stem cell ( PBSCs ) day -3 G-CSF IV begin day -3 continue blood count recover . Patients receive remain PBSCs day 0 . Patients undergo daily blood sample collection topotecan hydrochloride administration pharmacokinetic study . Patients treat maximum tolerated dose topotecan hydrochloride undergo additional blood sample collection pharmacokinetic study . After completion study therapy , patient follow every 3 month .</detailed_description>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm ovarian epithelial carcinoma , primary peritoneal cavity carcinoma , epithelial carcinoma fallopian tube , meet 1 follow criterion : Stage III IV disease treat initial therapy comprise standard platinumcontaining regimen Must &lt; 2 cm residual disease evidence disease progression initial chemotherapy AND disease progression immediately prior stem cell collection Patients initially present stage IV disease achieve clinical response ( complete response [ CR ] partial response [ PR ] ) initial therapy eligible Responding recurrent disease Patients recurrence elevate CA 125 level ( &gt; 100 U/mL ) achieve reduction CA 125 level 50 % 4 week follow recent course reinduction chemotherapy eligible Patients achieve CR PR salvage chemotherapy relapse disease eligible Patients measurable evaluable disease must achieve PR prior therapy No clinically significant pleural effusion PATIENT CHARACTERISTICS : Karnofsky performance status 70100 % ANC &gt; 1,000/μL Platelet count &gt; 100,000/μL Serum bilirubin &lt; 1.5 mg/dL SGOT SGPT ≤ 2.5 time normal Creatinine clearance ≥ 60 mL/min No active cardiac disease , opinion investigator , would preclude safe administration chemotherapy Cardiac ejection fraction normal rest MUGA No history potentially disable psychiatric disorder Hepatitis B antigen , hepatitis C antibody , HIV antibody negative No clinically significant peripheral neuropathy FEV_1 ≥ 2.0 L ≥ 75 % low limit normal PRIOR CONCURRENT THERAPY : See Disease Characteristics At least 4 week since prior chemotherapy radiotherapy No prior radiotherapy whole abdomen</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>fallopian tube cancer</keyword>
	<keyword>peritoneal cavity cancer</keyword>
</DOC>